Cambridge, UK and Leiden, The Netherlands, October 11, 2006. NovaThera Limited ("NovaThera") and biotech company Pharming Group NV ("Pharming") (Euronext: PHARM) (PHARM.AS) today announce the successful completion of their proof of concept studies designed to develop a new generation of bioactive materials. These materials are based on a fusion of the two companies' technologies - TheraGlass™ (a non-ceramic glass) and recombinant human proteins. The novel properties of such materials provide a new intellectual property portfolio for commercial exploitation.
